ALC Quote, Financials, Valuation and Earnings

CRISPR Therapeutics AG has a net margin of 11.35% compared to Alcon's net margin of -106.6%. Alcon's return on equity of 4.85% beat CRISPR Therapeutics AG's return on equity of -18.65%.

Alcon has a consensus price target of $106.65, signalling upside risk potential of 13.82%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.46 which suggests that it could grow by 111.36%. Given that CRISPR Therapeutics AG has higher upside potential than Alcon, analysts believe CRISPR Therapeutics AG is more attractive than Alcon.

Alcon has a beta of 0.987, which suggesting that the stock is 1.295% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.849, suggesting its more volatile than the S&P 500 by 84.861%.

Alcon has a quarterly dividend of $0.26 per share corresponding to a yield of 0.28%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alcon pays 12.77% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Alcon's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alcon quarterly revenues are $2.5B, which are larger than CRISPR Therapeutics AG quarterly revenues of $35M. Alcon's net income of $284M is higher than CRISPR Therapeutics AG's net income of -$37.3M. Notably, Alcon's price-to-earnings ratio is 45.71x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon is 4.70x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of 11.35% compared to Alcon's net margin of 20.79%. Alcon's return on equity of 4.85% beat Novartis AG's return on equity of 27.64%.

Alcon has a consensus price target of $106.65, signalling upside risk potential of 13.82%. On the other hand Novartis AG has an analysts' consensus of $112.26 which suggests that it could grow by 1.93%. Given that Alcon has higher upside potential than Novartis AG, analysts believe Alcon is more attractive than Novartis AG.

Alcon has a beta of 0.987, which suggesting that the stock is 1.295% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.564, suggesting its less volatile than the S&P 500 by 43.614%.

Alcon has a quarterly dividend of $0.26 per share corresponding to a yield of 0.28%. Novartis AG offers a yield of 3.63% to investors and pays a quarterly dividend of $3.99 per share. Alcon pays 12.77% of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Alcon quarterly revenues are $2.5B, which are smaller than Novartis AG quarterly revenues of $13.6B. Alcon's net income of $284M is lower than Novartis AG's net income of $2.8B. Notably, Alcon's price-to-earnings ratio is 45.71x while Novartis AG's PE ratio is 18.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon is 4.70x versus 4.33x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 11.35% compared to Alcon's net margin of --. Alcon's return on equity of 4.85% beat Roche Holding AG's return on equity of 23.8%.

Alcon has a consensus price target of $106.65, signalling upside risk potential of 13.82%. On the other hand Roche Holding AG has an analysts' consensus of $46.62 which suggests that it could grow by 19.12%. Given that Roche Holding AG has higher upside potential than Alcon, analysts believe Roche Holding AG is more attractive than Alcon.

Alcon has a beta of 0.987, which suggesting that the stock is 1.295% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.111%.

Alcon has a quarterly dividend of $0.26 per share corresponding to a yield of 0.28%. Roche Holding AG offers a yield of 3.48% to investors and pays a quarterly dividend of $1.36 per share. Alcon pays 12.77% of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Alcon quarterly revenues are $2.5B, which are larger than Roche Holding AG quarterly revenues of --. Alcon's net income of $284M is higher than Roche Holding AG's net income of --. Notably, Alcon's price-to-earnings ratio is 45.71x while Roche Holding AG's PE ratio is 27.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon is 4.70x versus 3.59x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.

Sandoz Group AG has a net margin of 11.35% compared to Alcon's net margin of -39.83%. Alcon's return on equity of 4.85% beat Sandoz Group AG's return on equity of --.

Alcon has a consensus price target of $106.65, signalling upside risk potential of 13.82%. On the other hand Sandoz Group AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Alcon has higher upside potential than Sandoz Group AG, analysts believe Alcon is more attractive than Sandoz Group AG.

Alcon has a beta of 0.987, which suggesting that the stock is 1.295% less volatile than S&P 500. In comparison Sandoz Group AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Alcon has a quarterly dividend of $0.26 per share corresponding to a yield of 0.28%. Sandoz Group AG offers a yield of 1.68% to investors and pays a quarterly dividend of $0.67 per share. Alcon pays 12.77% of its earnings as a dividend. Sandoz Group AG pays out -- of its earnings as a dividend. Alcon's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alcon quarterly revenues are $2.5B, which are larger than Sandoz Group AG quarterly revenues of $74.4M. Alcon's net income of $284M is higher than Sandoz Group AG's net income of -$29.6M. Notably, Alcon's price-to-earnings ratio is 45.71x while Sandoz Group AG's PE ratio is 26.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alcon is 4.70x versus 1.68x for Sandoz Group AG. Usually stocks with elevated PS ratios are considered overvalued.